BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6326784)

  • 1. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
    Roubin GS; Choong CY; Devenish-Meares S; Sadick NN; Fletcher PJ; Kelly DT; Harris PJ
    Circulation; 1984 May; 69(5):955-62. PubMed ID: 6142775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
    Glover DR; Wathen CG; Murray RG; Petch MC; Muir AL; Littler WA
    Br Heart J; 1985 Feb; 53(2):208-15. PubMed ID: 2857088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.
    Tweddel AC; Murray RG; Pearson D; Martin W; Hutton I
    Br Heart J; 1982 Apr; 47(4):375-80. PubMed ID: 6121566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results with prenalterol in patients with heart failure.
    Waagstein F; Reiz S; Ariniego R; Hjalmarson A
    Am Heart J; 1981 Sep; 102(3 Pt 2):548-54. PubMed ID: 7270401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure.
    Sharpe DN; Coxon R
    Eur J Clin Pharmacol; 1983; 25(4):539-45. PubMed ID: 6653650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contractile, coronary, and metabolic effects of the acute and long-term treatment of cardiac failure with prenalterol.
    Strauer BE; Bohn I; Hahn B; Kment A; Motz U
    J Cardiovasc Pharmacol; 1984; 6(3):491-8. PubMed ID: 6202977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose response study with oral prenalterol in patients with chronic congestive cardiac failure.
    Hendry WG; Comerford MB; Besterman EM
    Clin Cardiol; 1984 Jan; 7(1):23-8. PubMed ID: 6705284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prenalterol administered orally in patients with congestive heart failure.
    Hjalmarson A; Abelardo N; Caidahl K; Reyes C; Waagstein F; Wallentin I; Wikstrand J; Estrada-Yamamoto M
    Acta Med Scand Suppl; 1982; 659():201-20. PubMed ID: 6127890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of i.v. prenalterol in patients with severe cardiac failure at rest and during exercise.
    Doering W; Wauer B; Isbary J
    Acta Med Scand Suppl; 1982; 659():307-14. PubMed ID: 6127897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic effects of prenalterol in patients with severe congestive heart failure--NYHA III-IV.
    Erbel R; Meyer J; Schweizer P; Lambertz H; Voelker W; Effert S
    Acta Med Scand Suppl; 1982; 659():169-80. PubMed ID: 6127887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hemodynamic actions of prenalterol in left ventricular failure.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Acta Med Scand Suppl; 1982; 659():251-61. PubMed ID: 6127893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute haemodynamic effects of oral prenalterol in severe heart failure.
    Petch MC; Wisbey C; Ormerod O; Scott C; Goodfellow RM
    Br Heart J; 1984 Jul; 52(1):49-52. PubMed ID: 6146324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
    Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
    Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of intravenous prenalterol in severe heart failure.
    Kirlin PC; Pitt B
    Am J Cardiol; 1981 Mar; 47(3):670-5. PubMed ID: 7468501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure.
    Kupper W; Schütt M; Hamm CW; Kuck KH; Hanrath P; Bleifeld W
    Eur Heart J; 1983 Aug; 4(8):573-83. PubMed ID: 6139281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
    Waagstein F; Estrada-Yamamoto M; Reiz S; Reyes C; Hjalmarson A
    Acta Med Scand Suppl; 1982; 659():221-31. PubMed ID: 6127891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
    Fitzpatrick D; Ikram H; Nicholls MG; Espiner EA
    Circulation; 1983 Mar; 67(3):613-9. PubMed ID: 6821903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous prenalterol on haemodynamics and myocardial lactate extraction in patients with left ventricular failure.
    Kupper W; Schütt M; Bleifeld W
    Acta Med Scand Suppl; 1982; 659():287-98. PubMed ID: 6127895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulatory response to prenalterol in normal subjects and in patients with primary congestive cardiomyopathy.
    Guazzi MD; Qing LG; Olivari MT; Fiorentini C; Loaldi A; Bartorelli A; Moruzzi P; Polese A
    Acta Med Scand Suppl; 1982; 659():233-50. PubMed ID: 6127892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.